Charts

Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and IndirectlyNEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, was proud to unveil its poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday, April 10th. The poster details mechanism of acti

Gainers Protara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of ...

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces today that its CEO, Jeffrey Meckler will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference. The conference is being held on April 3 - 4, 2024 at Cooley Law, 55 Hudson Yards, New York, NY 10001. Presentation Date: April 3, 2024Time: 9:55am ETWebcast Link:

Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural killer cells, dendritic cells, Th1 CD4, and CD8 T cells NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that Dr. Michael Newman, Founder and Ch

Tribe Public Webinar with Indaptus Therapeutics Tribe Public Webinar with Indaptus Therapeutics “Fully Engaging The Human Immune System To Cure Disease,” Featuring CEO, Jeffrey MecklerRegistration now open at INDPMarch2024.TribePublic.com NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that its CEO, Jeffrey Meckler, will present and p

Indaptus Therapeutics (NASDAQ:INDP) reported its Q4 earnings results on Wednesday, March 13, 2024 at 07:30 AM. Here's what investors ...

Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, “We are thrilled with the progress we made in 2023, which

Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 74.5% to $1.85 during Monday's pre-market session. The company's ...

• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort • Single dose cohort data expected to be published at a scientific conference in 2024 NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces positive results from the second

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed ...

Shares of Okta, Inc. (NASDAQ: OKTA) shares rose sharply in today’s pre-market trading after the company reported ...

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today that Jeffrey A. Meckler, Chief Executive Officer, and Nir Sassi, Chief Financial Officer, will present a corporate update at the 2024 BIO CEO & Investor Conference. The conference is being held on February 26 – 27, 2024 at the New York Marriott Marquis. Presentation Date: Monday, Fe

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn

Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenzaNEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate stabilized packages of immune agonists to activate both innate (immediate) and adaptive (learned) cellular immune pathways, announces that the European P

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We continue to be encouraged by early results from our first cohort of patients in the INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors. As we recently reported and presented at the Society for Immunology in Cancer (SITC) conference, all four first

Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The ...

Poster presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer Showed Favorable Safety Profile and Achievement of Stable Disease in All Four Patients in First Cohort.NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate a stabilized package of immune agonists to activate both innate (immediate) and adaptive (learned) cellular im

Poster to be presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4, 2023 NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announces it will be presenting interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20. The interim data, released today in abstract form, demonstrated that as of August 31, 2023, each of the first cohort participants experienced transient activa

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVI. The conference is being held on October 3 – 5, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles. Event: LD Micro Main Event XVIPresentation Date: Tuesday, October 3Time: 12:30pm PT (Track 3)Webcast Link: https://me23.sequireevents.com/ A live webcast of the presentation can

Meet with Indaptus Therapeutics’ CEO Jeffrey Meckler Tribe Public Indaptus Event Tribe Public Indaptus Event NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus’ CEO, Jeffrey Meckler will present at Tribe Public’s Webinar Presentation and Q&A Event titled “Immunotherapy Reimagined." The Event is scheduled to begin at 8:30am pacific/11:30am eastern on Friday, September 29, 2023. To register to join the complimentary event, please visit t

Following evidence of marked pharmacodynamic activity in first cohort, Cohort 2 has dose reduced while anticipating a similar effectNEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-D101 trial. This cohort dose is a dose reduction from the previous cohort based on the significant pharmacodynamic effect seen with

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11 – 13, 2023 at the Lotte New York Palace Hotel. Presentation Date:September 13, 2023 Time:8:30am ET Webcast Link: https://journey.ct.events/view/a2bb617e-99c0-4e6c-8b4a-15d80a10a66f A live webcast of the

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

The Dow Jones closed lower by around 180 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or ...

NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We have recently announced the completion of the first cohort of patients in our INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors and receipt of authorization from the Safety Review Committee to advance into the second cohort. As previously announced,

Cohort 1 patients exhibited a significant immune response consistent with the mechanism of actionSafety Review Committee approved continuation to the next cohort of patients NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced completion of the first cohort of patients who received a single dose in Part 1 of its INDP-D101 trial of Decoy20 and the initiation of a new cohort following review of data by the Safety Revie

Roger Waltzman, M.D. Roger Waltzman, M.D. Appointed Chief Medical Officer of Indaptus Therapeutics NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D. as its Chief Medical Officer, effective August 7, 2023. Jeffrey Meckler, Indaptus’ CEO commented, “Roger’s deep experience in drug development, particularly in

Gainers CTI BioPharma (NASDAQ:CTIC) stock rose 85.1% to $8.92 during Wednesday's pre-market session. The company's market cap stands at ...

Analysts have provided the following ratings for Indaptus Therapeutics (NASDAQ:INDP) within the last quarter: Bullish Somewhat ...

LAS VEGAS, NV / ACCESSWIRE / April 24, 2023 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 25-27, 2023, where 77 MicroCap public and private companies will be presenting at the Horseshoe Hotel & Casino in Las Vegas, NV.

Indaptus Therapeutics Inc (NASDAQ: INDP) announces data presented in a poster at the American Association for Cancer Research (AACR) ...

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, ...

Gainers OpGen (NASDAQ:OPGN) stock rose 69.6% to $0.21 during Tuesday's pre-market session. The market value of their outstanding shares ...

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Indaptus Therapeutics (NASDAQ:INDP) reported its Q2 earnings results on Monday, August 8, 2022 at 08:00 AM. Here's what ...

Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to ...

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 ...

Gainers Leju Holdings Limited (NYSE: LEJU) surged 27.8% to $4.0413. TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 25.6% to ...

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA ...

Gainers Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's ...

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Indaptus Therapeutics (INDP) stock is soaring higher on Thursday following an update from the U.S. Food and Drug Administration (FDA). The post Why Is Indaptus Therapeutics (INDP) Stock Up 20% Today? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

The U.S. Food and Drug Administration (FDA) has announced clearance to Indaptus Therapeutics’ (NASDAQ: INDP) Investigational New ...

Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 28.8% to $3.22 during Thursday's pre-market ...

Indaptus Therapeutics (NASDAQ:INDP) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what ...

Indaptus Therapeutics (NASDAQ:INDP) reported its Q4 earnings results on Monday, March 21, 2022 at 07:00 AM. Here's what ...

Gainers Immutep (NASDAQ:IMMP) stock rose 18.1% to $3.39 during Wednesday's after-market session. Today's trading volume for this ...

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 62.1% to $1.05 in pre-market trading as the company issued a clinical and ...

Gainers Indaptus Therapeutics (NASDAQ:INDP) stock rose 6.6% to $6.58 during Monday's after-market session. Today's trading volume for ...

Gainers Nutriband Inc. (NASDAQ: NTRB) shares jumped 120.2% to $8.61 after the company announced the Korean Intellectual Property ...

Maximanalyst has upgradedIndaptus Therapeutics Inc(NASDAQ: INDP) to Buy from Hold with a $16 price target, an ...

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:INDP) from Hold to Buy. Indaptus Therapeutics ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 ...

Gainers Atea Pharmaceuticals (NASDAQ:AVIR) shares increased by 13.83% to $29.86 during Monday's regular session. ...

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. ...

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) shares rose 78.31% to $4.03 during Friday's regular session. The current volume of ...

Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 27.72% to $2.46 during Thursday's regular session. As ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning. investor! We're over halfway through the week now but we're not slacking with our biggest pre-market stock movers for Thursday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO ...